136 related articles for article (PubMed ID: 36803869)
1. Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
Morais A; Morais J; Felix M; Neto Z; Madaleno V; Umar AS; Panda N; Lemma F; Chivale JAL; Cavalcante DG; Davlantes E; Ghiselli M; Espinosa C; Whiteman A; Iber J; Henderson E; Bullard K; Jorba J; Burns CC; Diop O; Gumede N; Seakamela L; Howard W; Frawley A
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A48-A57. PubMed ID: 36803869
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
[TBL] [Abstract][Full Text] [Related]
4. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.
Macklin GR; Goel AK; Mach O; Tallis G; Ahmed JA; O'Reilly KM; Grassly NC; Diop OM
Vaccine; 2023 Apr; 41 Suppl 1():A19-A24. PubMed ID: 36008232
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-Derived Poliovirus Outbreaks and Events - Three Provinces, Democratic Republic of the Congo, 2017.
Alleman MM; Chitale R; Burns CC; Iber J; Dybdahl-Sissoko N; Chen Q; Van Koko DR; Ewetola R; Riziki Y; Kavunga-Membo H; Dah C; Andriamihantanirina R
MMWR Morb Mortal Wkly Rep; 2018 Mar; 67(10):300-305. PubMed ID: 29543791
[TBL] [Abstract][Full Text] [Related]
7. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
[TBL] [Abstract][Full Text] [Related]
8. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925
[TBL] [Abstract][Full Text] [Related]
9. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
Alleman MM; Jorba J; Henderson E; Diop OM; Shaukat S; Traoré MA; Wiesen E; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1691-1699. PubMed ID: 34882653
[TBL] [Abstract][Full Text] [Related]
10. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.
Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG
Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838
[TBL] [Abstract][Full Text] [Related]
11. Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
Snider CJ; Boualam L; Tallis G; Takashima Y; Abeyasinghe R; Lo YR; Grabovac V; Avagyan T; Aslam SK; Eltayeb AO; Aung KD; Wang X; Shrestha A; Ante-Orozco C; Silva MWT; Lapastora-Sucaldito N; Apostol LNG; Jikal MBH; Miraj W; Lodhi F; Kim HJ; Rusli N; Thorley BR; Kaye MB; Nishimura Y; Arita M; Sani JAM; Rundi C; Feldon K
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A58-A69. PubMed ID: 35337673
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
[TBL] [Abstract][Full Text] [Related]
13. A circulating vaccine-derived poliovirus type 2 outbreak in a chronic conflict setting: a descriptive epidemiological study in South Sudan - 2020 to 2021.
Tegegne AA; Anyuon AN; Legge GA; Ferede MA; Isaac Z; Laku KA; Biadgilign S; Kilo OTD; Ndenzako F; Modjirom N; Olu OO; Maleghemi S
BMC Infect Dis; 2023 Nov; 23(1):816. PubMed ID: 37990165
[TBL] [Abstract][Full Text] [Related]
14. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.
Bigouette JP; Henderson E; Traoré MA; Wassilak SGF; Jorba J; Mahoney F; Bolu O; Diop OM; Burns CC
MMWR Morb Mortal Wkly Rep; 2023 Apr; 72(14):366-371. PubMed ID: 37022974
[TBL] [Abstract][Full Text] [Related]
15. Update on Vaccine-Derived Poliovirus Outbreaks - Democratic Republic of the Congo and Horn of Africa, 2017-2018.
Mbaeyi C; Alleman MM; Ehrhardt D; Wiesen E; Burns CC; Liu H; Ewetola R; Seakamela L; Mdodo R; Ndoutabe M; Wenye PK; Riziki Y; Borus P; Kamugisha C; Wassilak SGF
MMWR Morb Mortal Wkly Rep; 2019 Mar; 68(9):225-230. PubMed ID: 30845121
[TBL] [Abstract][Full Text] [Related]
16. Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
Molodecky NA; Jafari H; Safdar RM; Ahmed JA; Mahamud A; Bandyopadhyay AS; Shukla H; Quddus A; Zaffran M; Sutter RW; Grassly NC; Blake IM
Vaccine; 2023 Apr; 41 Suppl 1():A93-A104. PubMed ID: 34629206
[TBL] [Abstract][Full Text] [Related]
17. Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.
Al-Qassimi MA; Al Amad M; Al-Dar A; Al Sakaf E; Al Hadad A; Raja'a YA
BMC Infect Dis; 2024 Mar; 24(1):321. PubMed ID: 38491425
[TBL] [Abstract][Full Text] [Related]
18. Stopping a polio outbreak in the midst of war: Lessons from Syria.
Mbaeyi C; Moran T; Wadood Z; Ather F; Sykes E; Nikulin J; Al Safadi M; Stehling-Ariza T; Zomahoun L; Ismaili A; Abourshaid N; Asghar H; Korukluoglu G; Duizer E; Ehrhardt D; Burns CC; Sharaf M
Vaccine; 2021 Jun; 39(28):3717-3723. PubMed ID: 34053791
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
[TBL] [Abstract][Full Text] [Related]
20. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
